title: Developing chemical genetic approaches to explore G protein-coupled receptor function: validation of the use of a receptor activated solely by synthetic ligand (RASSL).
abstract: Molecular evolution and chemical genetics have been applied to generate functional pairings of mutated G protein-coupled receptors (GPCRs) and nonendogenous ligands. These mutant receptors, referred to as receptors activated solely by synthetic ligands (RASSLs) or designer receptors exclusively activated by designer drugs (DREADDs), have huge potential to define physiological roles of GPCRs and to validate receptors in animal models as therapeutic targets to treat human disease. However, appreciation of ligand bias and functional selectivity of different ligands at the same receptor suggests that RASSLs may signal differently than wild-type receptors activated by endogenous agonists. We assessed this by generating forms of wild-type human M(3) muscarinic receptor and a RASSL variant that responds selectively to clozapine N-oxide. Although the RASSL receptor had reduced affinity for muscarinic antagonists, including atropine, stimulation with clozapine N-oxide produced effects very similar to those generated by acetylcholine at the wild-type M(3)-receptor. Such effects included the relative movement of the third intracellular loop and C-terminal tail of intramolecular fluorescence resonance energy transfer sensors and the ability of the wild type and evolved mutant to regulate extracellular signal-regulated kinase 1/2 phosphorylation. Each form interacted similarly with β-arrestin 2 and was internalized from the cell surface in response to the appropriate ligand. Furthermore, the pattern of phosphorylation of specific serine residues within the evolved receptor in response to clozapine N-oxide was very similar to that produced by acetylcholine at the wild type. Such results provide confidence that, at least for the M(3) muscarinic receptor, results obtained after transgenic expression of this RASSL are likely to mirror the actions of acetylcholine at the wild type receptor.
authors: Molecular Pharmacology Group, Institute of Neuroscience and Psychology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom.
authors: Elisa
authors: E
authors: Alvarez-Curto
authors: Rudi
authors: R
authors: Prihandoko
authors: Christofer S
authors: CS
authors: Tautermann
authors: Jurriaan M
authors: JM
authors: Zwier
authors: John D
authors: JD
authors: Pediani
authors: Martin J
authors: MJ
authors: Lohse
authors: Carsten
authors: C
authors: Hoffmann
authors: Andrew B
authors: AB
authors: Tobin
authors: Graeme
authors: G
authors: Milligan
mesh_terms: D057809:HEK293 Cells; D006801:Humans; D008024:Ligands; D016297:Mutagenesis, Site-Directed / Q000379:methods / Q000592:standards*; D043587:Receptor, Muscarinic M3 / Q000737:chemistry / Q000502:physiology*; D043562:Receptors, G-Protein-Coupled / Q000235:genetics* / Q000378:metabolism*; D017473:Receptors, Opioid, kappa / Q000235:genetics / Q000378:metabolism*; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000378:metabolism*; D015203:Reproducibility of Results
chemical_list: D008024:Ligands; D043587:Receptor, Muscarinic M3; D043562:Receptors, G-Protein-Coupled; D017473:Receptors, Opioid, kappa; D011993:Recombinant Fusion Proteins; C110261:Ro2 protein, recombinant